Evidence map›Paper›PMID 28630086›Full record

Trial reportBMJ open2017

Psychosocial therapy for Parkinson's-related dementia: study protocol for the INVEST randomised controlled trial.

Sheree A McCormick, Kathryn R McDonald, Sabina Vatter, Vasiliki Orgeta, Ellen Poliakoff, Sarah Smith, Monty A Silverdale, Bo Fu, Iracema Leroi

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMJ open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Sheree A McCormickDivision of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK.
Kathryn R McDonaldDivision of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK.
Sabina VatterDivision of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK.
Vasiliki OrgetaDivision of Psychiatry, University College London, London, UK.
Ellen PoliakoffDivision of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK.
Sarah SmithFaculty of Health Studies, University of Bradford, Bradford, UK.
Monty A SilverdaleManchester Academic Health Science Centre, Manchester, UK.
Bo FuDivision of Psychiatry, University College London, London, UK.
Iracema LeroiDivision of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK.
Manchester Academic Health Science Centre · GBUniversity College London · GBGreater Manchester Mental Health NHS Foundation Trust · GBSalford Royal NHS Foundation Trust · GBUniversity of Bradford · GBUniversity of Manchester · GB

Funding

Department of Health PB-PG-0613-31058
6 · The paper itself

Abstract

introductionParkinson's disease (PD) with mild cognitive impairment (MCI-PD) or dementia (PDD) and dementia with Lewy bodies (DLB) are characterised by motor and 'non-motor' symptoms which impact on quality of life. Treatment options are generally limited to pharmacological approaches. We developed a psychosocial intervention to improve cognition, quality of life and companion burden for people with MCI-PD, PDD or DLB. Here, we describe the protocol for a single-blind randomised controlled trial to assess feasibility, acceptability and tolerability of the intervention and to evaluate treatment implementation. The interaction among the intervention and selected outcome measures and the efficacy of this intervention in improving cognition for people with MCI-PD, PDD or DLB will also be explored. METHODS AND ANALYSIS: Dyads will be randomised into two treatment arms to receive either 'treatment as usual' (TAU) or cognitive stimulation therapy specifically adapted for Parkinson's-related dementias (CST-PD), involving 30 min sessions delivered at home by the study companion three times per week over 10 weeks. A mixed-methods approach will be used to collect data on the operational aspects of the trial and treatment implementation. This will involve diary keeping, telephone follow-ups, dyad checklists and researcher ratings. Analysis will include descriptive statistics summarising recruitment, acceptability and tolerance of the intervention, and treatment implementation. To pilot an outcome measure of efficacy, we will undertake an inferential analysis to test our hypothesis that compared with TAU, CST-PD improves cognition. Qualitative approaches using thematic analysis will also be applied. Our findings will inform a larger definitive trial. ETHICS AND DISSEMINATION: Ethical opinion was granted (REC reference: 15/YH/0531). Findings will be published in peer-reviewed journals and at conferences. We will prepare reports for dissemination by organisations involved with PD and dementia. TRIAL REGISTRATION NUMBER: ISRCTN (ISRCTN11455062).

Indexed as

Cognitive DysfunctionCost of IllnessLewy Body DiseaseParkinson DiseaseQuality of LifeBehavioral SymptomsCaregiversDisease ManagementFemaleHumansMaleResearch DesignSpousesSymptom AssessmentTreatment Outcomecomplex interventiondementia with Lewy bodies (DLB)feasibility and exploratory studymild cognitive impairment in PD (MCI-PD)parkinson’s disease dementia (PDD)pilot trialprocess analysis.psychosocial therapyquality of life

Identifiers

PMID28630086
PMCPMC5726123
OpenAlexW2687524919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.